Please assess the completion status of the following clinical trial:

Trial Title: Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obtention of a written informed consent.~* Patient over 18.~* Patient with histologically proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing, bile cytology, endobiliary biopsy under Spyglass, or by EUS-FNA.~* Patient with Karnofsky score ≥ 50 %~* Patient capable of fill in the quality of life questionnaire.~Exclusion Criteria:~* No written informed consent.~* Patients under or already treated by radiotherapy or chemotherapy treatment for cholangiocarcinoma.~* Patients with porphyria or hypersensibility to porphyrins.~* Pregnant, parturient or breastfeeding women.~* Patient under 18.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RFA+stent+S-1 (Type: EXPERIMENTAL): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
- RFA+stent (Type: PLACEBO_COMPARATOR): Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement

Based on this trial design, predict the completion outcome and termination type (if applicable).